Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3‑kinase/protein kinase B signaling

Chen,Xiaofeng; Kuang,Weiping; Huang,Hongxing; Li,Bo; Zhu,Yong; Zhou,Bin; Yan,Lin

doi:10.3892/etm.2018.6135

Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3‑kinase/protein kinase B signaling

Authors:
- Xiaofeng Chen
- Weiping Kuang
- Hongxing Huang
- Bo Li
- Yong Zhu
- Bin Zhou
- Lin Yan
View Affiliations

Affiliations: Department of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China
Published online on: May 7, 2018 https://doi.org/10.3892/etm.2018.6135
Pages: 384-393

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma is the most common and malignant primary brain tumor. RWD domain containing 3 (RWDD3) has been previously reported to serve a promoting role in pituitary tumors. However, the exact role of RWDD3 in glioblastoma remains unclear. Therefore, the present study aimed to investigate the expression levels of RWDD3 in human glioblastoma tissues and cell lines, as well as to examine the regulatory mechanism of RWDD3 underlying glioblastoma growth and metastasis. The results revealed that RWDD3 was significantly upregulated in glioblastoma tissues compared with normal brain tissues, while high expression of RWDD3 was associated with a shorter survival time of glioblastoma patients. The expression levels of RWDD3 were also higher in the glioblastoma cell lines compared with the normal human astrocyte cell line. Subsequent to knockdown of RWDD3, the proliferation of glioblastoma U87 and U251 cells was significantly decreased, possibly due to the cell cycle arrest at G1 phase, as well as the increased cell apoptosis. Furthermore, downregulation of RWDD3 also suppressed U87 and U251 cell invasion by inhibiting the expression levels of matrix metalloproteinase 2 (MMP2) and MMP9. Molecular mechanism investigation demonstrated that knockdown of RWDD3 significantly downregulated the activity of the phosphoinositide 3‑kinase/protein kinase B (PI3K/AKT) signaling pathway. Activation of PI3K/AKT signaling prevented the suppressive effects of RWDD3 downregulation on glioblastoma cell proliferation and migration, concurrent with increased protein levels of MMP2 and MMP9. In conclusion, the current study demonstrated for the first time that inhibition of RWDD3 expression inhibited glioblastoma progression, at least partly, via suppressing the PI3K/AKT signaling activity, and thus RWDD3 may be a novel potential therapeutic target for glioblastoma.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Li Z, Guo J, Ma Y, Lin Z and Zhang L: Oncogenic role of MicroRNA-30b-5p in glioblastoma through targeting proline-rich transmembrane protein 2. Oncol Res. May 17–2017.(Epub ahead of print).
3	Ding B, Cui B, Gao M, Li Z, Xu C, Fan S and He W: Knockdown of ras-related protein 25 (Rab25) inhibits the in vitro cytotoxicity and in vivo antitumor activity of human glioblastoma multiforme cells. Oncol Res. 25:331–340. 2017. View Article : Google Scholar : PubMed/NCBI
4	Liu J, Li W, Liu S, Zheng X, Shi L, Zhang W and Yang H: Knockdown of collagen triple helix repeat containing 1 (CTHRC1) inhibits epithelial-mesenchymal transition and cellular migration in glioblastoma cells. Oncol Res. 25:225–232. 2017. View Article : Google Scholar : PubMed/NCBI
5	Arciuch Antico VG, Tedesco L, Fuertes M and Arzt E: Role of RSUME in inflammation and cancer. FEBS Lett. 589:3330–3335. 2015. View Article : Google Scholar : PubMed/NCBI
6	Liberman AC, Druker J, Garcia FA, Holsboer F and Arzt E: Intracellular molecular signaling. Basis for specificity to glucocorticoid anti-inflammatory actions. Ann N Y Acad Sci. 1153:6–13. 2009. View Article : Google Scholar : PubMed/NCBI
7	Druker J, Liberman AC, Antunica-Noguerol M, Gerez J, Paez-Pereda M, Rein T, Iñiguez-Lluhí JA, Holsboer F and Arzt E: RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity. Mol Cell Biol. 33:2116–2127. 2013. View Article : Google Scholar : PubMed/NCBI
8	Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F and Arzt E: RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell. 131:309–323. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wu Y, Tedesco L, Lucia K, Schlitter AM, Garcia JM, Esposito I, Auernhammer CJ, Theodoropoulou M, Arzt E, Renner U and Stalla GK: RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors. Oncotarget. 7:57878–57893. 2016.PubMed/NCBI
10	Fuertes M, Gerez J, Haedo M, Giacomini D, Páez-Pereda M, Labeur M, Stalla GK and Arzt E: Cytokines and genes in pituitary tumorigenesis: RSUME role in cell biology. Front Horm Res. 38:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
11	Shan B, Gerez J, Haedo M, Fuertes M, Theodoropoulou M, Buchfelder M, Losa M, Stalla GK, Arzt E and Renner U: RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells. Endocr Relat Cancer. 19:13–27. 2012. View Article : Google Scholar : PubMed/NCBI
12	Gerez J, Tedesco L, Bonfiglio JJ, Fuertes M, Barontini M, Silberstein S, Wu Y, Renner U, Páez-Pereda M, Holsboer F, et al: RSUME inhibits VHL and regulates its tumor suppressor function. Oncogene. 34:4855–4866. 2015. View Article : Google Scholar : PubMed/NCBI
13	Fan YH, Zhu XG, WU MJ, Chai Y, YE MH, Xi-Ao B and Wu L: Effects of lentivirus-mediated RWDD3 silencing on proliferation and invasion of human glioma U251 cells. Chin J Pathophysiol. 31:1550–1556. 2015.
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Katase N, Nishimatsu SI, Yamauchi A, Yamamura M, Terada K, Itadani M, Okada N, Hassan NMM, Nagatsuka H, Ikeda T, et al: DKK3 overexpression increases malignant properties of head and neck squamous cell carcinoma cells. Oncol Res. 26:45–58. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zhao P, Guan HT, Dai ZJ, Ma YG, Liu XX and Wang XJ: Knockdown of SPOCK1 inhibits the proliferation and invasion in colorectal cancer cells by suppressing the PI3K/Akt pathway. Oncol Res. 24:437–445. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wu W, Hu Q, Nie E, Yu T, Wu Y, Zhi T, Jiang K, Shen F, Wang Y, Zhang J and You Y: Hypoxia induces H19 expression through direct and indirect Hif-1α activity, promoting oncogenic effects in glioblastoma. Sci Rep. 7:450292017. View Article : Google Scholar : PubMed/NCBI
18	Gabriely G, Wheeler MA, Takenaka MC and Quintana FJ: Role of AHR and HIF-1α in glioblastoma metabolism. Trends Endocrinol Metab. 28:428–436. 2017. View Article : Google Scholar : PubMed/NCBI
19	Liu M, Wang D and Li N: MicroRNA-20b downregulates HIF-1α and Inhibits the proliferation and invasion of osteosarcoma cells. Oncol Res. 23:257–266. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhou Y, Yang C, Wang K, Liu X and Liu Q: MicroRNA-33b inhibits the proliferation and migration of osteosarcoma cells via targeting hypoxia-inducible factor-1α. Oncol Res. 25:397–405. 2017. View Article : Google Scholar : PubMed/NCBI
21	Liu F, Lin B, Liu X, Zhang W, Zhang E, Hu L, Ma Y, Li X and Tang X: ERK signaling pathway is involved in HPV-16 E6 but not E7 oncoprotein-induced HIF-1α protein accumulation in NSCLC cells. Oncol Res. 23:109–118. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wang F, Cai F, Shi R, Wei JN and Wu XT: Hypoxia regulates sumoylation pathways in intervertebral disc cells: Implications for hypoxic adaptations. Osteoarthritis Cartilage. 24:1113–1124. 2016. View Article : Google Scholar : PubMed/NCBI
23	Gerez J, Fuertes M, Tedesco L, Silberstein S, Sevlever G, Paez-Pereda M, Holsboer F, Turjanski AG and Arzt E: In silico structural and functional characterization of the RSUME splice variants. PLoS One. 8:e577952013. View Article : Google Scholar : PubMed/NCBI
24	Xue Q, Cao L, Chen XY, Zhao J, Gao L, Li SZ and Fei Z: High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett. 13:1325–1330. 2017. View Article : Google Scholar : PubMed/NCBI
25	Zhu Y, Zhang X, Wang L, Ji Z, Xie M, Zhou X, Liu Z, Shi H and Yu R: Loss of SH3GL2 promotes the migration and invasion behaviours of glioblastoma cells through activating the STAT3/MMP2 signalling. J Cell Mol Med. 21:2685–2694. 2017. View Article : Google Scholar : PubMed/NCBI
26	Miao Y, Lu M, Yan Q, Li S and Feng Y: Inhibition of proliferation, migration, and invasion by knockdown of pyruvate kinase-M2 (PKM2) in ovarian cancer SKOV3 and OVCAR3 cells. Oncol Res. 24:463–475. 2016. View Article : Google Scholar : PubMed/NCBI
27	Amar S, Minond D and Fields GB: Clinical implications of compounds designed to inhibit ECM-modifying metalloproteinases. Proteomics. 17(23–24)2017.PubMed/NCBI
28	Zhang J, Yu XH, Yan YG, Wang C and Wang WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
29	Ramezani S, Vousooghi N, Kapourchali Ramezani F and Joghataei MT: Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model. Apoptosis. 22:1025–2034. 2017. View Article : Google Scholar : PubMed/NCBI
30	Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST and Li WP: Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development. Mol Cancer. 16:1002017. View Article : Google Scholar : PubMed/NCBI